This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Report: Swiss Drugmaker Nycomed Shopping Itself

NEW YORK (AP) ¿ Swiss drug company Nycomed could be in the market sell itself for as much as 10 billion euro, or $13.57 billion, according to a media report Monday.

The Wall Street Journal reported that the privately held company had engaged Goldman Sachs to help find a buyer but might also consider options including new drug licenses or an initial public offering. Nycomed, which is based in Zurich, did not immediately return calls seeking comment.

Goldman Sachs declined to comment.

At the reported sale price, Nycomed would fetch a far lower value than Wyeth, which was recently sold to Pfizer Inc. for $68 billion, and Schering-Plough, bought by Merck for $44.1 billion. But $13.57 billion would be more than double what Eli Lilly & Co. paid for ImClone Systems Inc. last fall.

Nycomed makes almost half its sales to European markets, including a strong presence in eastern Europe. The company describes itself as one of the 25 largest drugmakers in the world, and the 15th-largest seller of over-the-counter medicines. Nycomed says it focuses on gastroenterology, pain management, osteoporosis, respiratory diseases and tissue management.

Nycomed licenses the heartburn drug Protonix to Wyeth in the U.S. Nycomed also has partnerships with NPS Pharmaceuticals Inc., Immunomedics Inc., Sepracor Inc., Micromet Inc. and Baxter International Inc., among others.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMCL $0.13 -3.95%
BAX $45.09 -0.46%
IMMU $3.63 4.90%
NPSP $45.97 0.02%
PFE $33.51 -0.18%


Chart of I:DJI
DOW 17,715.47 +54.76 0.31%
S&P 500 2,054.55 +3.92 0.19%
NASDAQ 4,727.3670 +10.2730 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs